| Mr Talmage Jay Broadbent, MD,PHD | |
|
626 S. Sheridan St, Spokane, WA 99202-1325 | |
| (509) 279-2176 | |
| (509) 279-2941 |
| Full Name | Mr Talmage Jay Broadbent |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 13 Years |
| Location | 626 S. Sheridan St, Spokane, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043507205 | NPI | - | NPPES |
| 2079499 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 58899 (Minnesota) | Secondary |
| 207WX0200X | Ophthalmology - Ophthalmic Plastic And Reconstructive Surgery | MD60704061 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prov Sacred Hrt Med Ctr & Childs Hosp. | Spokane, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Eyelid And Orbital Specialists Ps | 9133252935 | 2 |
News Archive
State officials in California are moving to define standards for insurers hoping to participate in the insurance exchanges, while a legislative committee in Colorado gives the state permission to continue building its exchange.
Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has executed a definitive agreement with the Department of Justice (DOJ) and the Office of Inspector General of the Department of Health and Human Services to resolve the issues raised in the DOJ's investigation and the related qui tam complaint regarding the marketing of the Company's surgical ablation devices.
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.
› Verified 6 days ago
| Entity Name | Northwest Eyelid And Orbital Specialists Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053637702 PECOS PAC ID: 9133252935 Enrollment ID: O20100730000424 |
News Archive
State officials in California are moving to define standards for insurers hoping to participate in the insurance exchanges, while a legislative committee in Colorado gives the state permission to continue building its exchange.
Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has executed a definitive agreement with the Department of Justice (DOJ) and the Office of Inspector General of the Department of Health and Human Services to resolve the issues raised in the DOJ's investigation and the related qui tam complaint regarding the marketing of the Company's surgical ablation devices.
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Talmage Jay Broadbent, MD,PHD 626 S. Sheridan St, Spokane, WA 99202-1325 Ph: (509) 279-2176 | Mr Talmage Jay Broadbent, MD,PHD 626 S. Sheridan St, Spokane, WA 99202-1325 Ph: (509) 279-2176 |
News Archive
State officials in California are moving to define standards for insurers hoping to participate in the insurance exchanges, while a legislative committee in Colorado gives the state permission to continue building its exchange.
Aeterna Zentaris Inc. today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted.
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has executed a definitive agreement with the Department of Justice (DOJ) and the Office of Inspector General of the Department of Health and Human Services to resolve the issues raised in the DOJ's investigation and the related qui tam complaint regarding the marketing of the Company's surgical ablation devices.
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.
› Verified 6 days ago
Dr. Jeffery M. Snow, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 427 S Bernard St, Spokane, WA 99204 Phone: 509-456-0107 Fax: 509-747-2635 | |
Robert Samuel Wirthlin, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 427 S Bernard St, Spokane, WA 99204 Phone: 509-456-0107 Fax: 509-747-2635 | |
Neal J. Peterson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 510 S Cowley St, Spokane, WA 99202 Phone: 509-838-2531 | |
Christian Spencer Draper, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9911 N Nevada St Ste B, Spokane, WA 99218 Phone: 509-484-5710 Fax: 509-487-1000 | |
Dr. Erik Dale Skoog, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 427 S Bernard St, Spokane, WA 99204 Phone: 509-456-0107 Fax: 509-747-2635 | |
Dr. Barbara A. Smit, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 427 S Bernard St, Spokane, WA 99204 Phone: 509-456-0107 Fax: 509-747-2635 |